Only one of our models could value this stock with confidence, so use it as a guide.
Not used by alerts or posts.
Valued as a growth company: P/E comparison and EV/EBITDA comparison.
ACCE opinionTG Therapeutics Inc. Common Stock (TGTX)
Fair value (3 models)
Not available
ACCE price target
$53.50
Rating
Not rated
Horizon
12 months
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Price used: $54.17 at the close on 23 Oct 2026, 22:00 CEST.
Models: EV/EBITDA comparison and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
71
out of 100
Analysts
88% buy
8 covering
P/E
19.7x
forward 20.0x
1-year return
+61.7%
Dividend yield
0.00%
TG Therapeutics Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
TG Therapeutics sells Briumvi (ublituximab), an anti-CD20 infusion for relapsing and non-relapsing multiple sclerosis, and is building a franchise in B-cell-driven autoimmune disease. Its structural edge is a differentiated, shorter infusion regimen against the incumbent anti-CD20 antibodies, which supports a product with an 82.4% gross margin. Revenue growth of 70.3% reflects Briumvi's ramp as it takes share from established MS infusions, and the next leg depends on uptake in the expanding patient base and label progress in adjacent indications. At an $8.6 billion market cap the shares trade at 25.9x forward earnings against a 9.0% operating margin, so the bet is that operating leverage arrives as the revenue base scales. The multiple leaves little room for a stumble in launch execution, so this merits a deeper look at the commercial trajectory and cash burn before any further step.